Skip to main content

Table 1 Participant overview

From: Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

  Total cohort Control MCI AD
Urine     
 Participants 556 171 209 176
 Male/female 269/287 83/88 95/114 91/85
 Mean age (SD) 76.24 (5.76) 75.85 (5.17) 76.33 (6.03) 76.53 (5.99)
 MMSE score 25.67 (4.59) 28.73 (1.92) 26.86 (2.75) 21.17 (4.87)
 CDR 0.56 (0.51) 0.07 (0.18) 0.49 (0.08) 1.10 (0.54)
 Reported SSRI medication 43 4 16 23
Serum     
 Participants 354 86 165 103
 Male/female 165/189 44/42 71/94 50/53
 Mean age 76.95 (6.13) 75.97 (5.67) 77.50 (6.49) 76.91 (5.84)
 MMSE score 25.57 (4.37) 28.80 (1.99) 26.73 (2.24) 21.06 (4.79)
 CDR 0.59 (0.54) 0.04 (0.16) 0.49 (0.11) 1.16 (0.55)
 Reported SSRI medication 30 1 11 18
  1. Overview of the sample cohort used in the study. SSRI selective serotonin reuptake inhibitor, MCI mild cognitive impairment, AD Alzheimer’s disease, MMSE Mini-Mental State Examination score, CDR Clinical Dementia Rating